Repeat kidney biopsy in new lupus kidney disease
Part of Immune system & allergy, Kidney & urinary, Skin, Women’s health & pregnancy clinical trials.
This study looks at whether doing a planned second kidney biopsy about 12 months later helps doctors understand and guide treatment for people with newly diagnosed lupus nephritis. You may be put on standard lupus-kidney medications, and the main “test” is the repeat biopsy timing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lupus (SLE) that meets specific standard classification rules
- You are 18 years or older
- You were recently diagnosed with biopsy-proven lupus kidney disease (proliferative or membranous types) and have a urine protein level of at least 1 g/g (UPCR)
- You can start the study’s usual lupus-kidney treatment plan (steroid plus hydroxychloroquine and additional medicine like mycophenolate or cyclophosphamide)
- You must be willing and able to have a repeat kidney biopsy about 12 months after the first one
- You are not pregnant at the start of the study and you do not have serious reasons you can’t safely have a biopsy (for example, very low platelets or uncontrolled blood pressure)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking for biomarkers (clues in your blood, urine, or tissue) that can help predict how well lupus nephritis (kidney inflammation caused by lupus) responds to treatment. It focuses on people who have active kidney disease and are either starting treatment or have been on a stable treatment for at least a month.
This study looks at blood and urine markers that may show how active lupus kidney disease is and how it changes over time. It may help doctors better monitor people with active lupus-related kidney inflammation.
This study looks at whether a specific antibody (anti-alpha-actinin) in the blood is linked to active lupus kidney disease. It may help doctors better understand and monitor kidney problems in people with lupus.
This study aims to find better ways to detect kidney problems in people with lupus by testing blood and urine samples. If you have lupus, you may help researchers improve how kidney disease is diagnosed and monitored.
This study tests whether adding LUPKYNIS (a drug that protects the kidney) to one of three immune-system medications helps people with lupus nephritis (lupus affecting the kidneys). The goal is to reduce protein in urine and protect kidney function.
This Phase 2 study tests whether LNP023 can improve outcomes and safety in people with active lupus nephritis (lupus-related kidney inflammation), class III or IV. It may help by targeting the ongoing immune activity that is damaging the kidneys.
Hear when a new Lupus Nephritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.